Article Text

Download PDFPDF
CP-100 Pegylated interferon ALFA 2-A in myeloproliferative neoplasms
  1. M Scaldaferri,
  2. A Varese,
  3. M Tonelli,
  4. D Barilà,
  5. A Bianco,
  6. G Valinotti,
  7. E Caiazza,
  8. D Martinetto,
  9. M Ferroni,
  10. F Cattel
  1. Città della Salute e della Scienza di Torino, Pharmacy, Torino, Italy


Background Polycythaemia vera (PV), essential thrombocythemia (TE) and myelofibrosis (MF) are myeloproliferative neoplasms (MPN), characterised by a number of mutations related to proliferation and differentiation of myeloid cell lines. Peg-interferon α2a (P-IFN) is considered a promising option for the therapy of these pathologies, although in Italy this is an off-label use, as an alternative to hydroxyurea.

Purpose Evaluation of the therapeutic efficacy and tolerability of P-IFN in a cohort of PV, TE and MF patients treated according to an off-label protocol.

Material and methods The analysis consisted of review of the medical records of all patients with a diagnosis of PV, TE or MF, who were treated with P-IFN since 2010.

Results 38 patients were treated with P-IFN for MPN. 30 patients (79%) had a diagnosis of PV and 81.5% were positive for the JAK2 mutation; 89.5% of patients were undergoing phlebotomy treatment. P-IFN was used as firstline therapy in 21.00% of patients; the remaining 79% of patients previously received other treatments, mainly hydroxyurea (96.5% of previously treated patients). P-IFN was started because of the young age of patients (13.1%), to ameliorate the quality of life of patients (13.1%) or because of lack of response to previous treatments. Doses of P-IFN ranged from 45 μg/week to 145 μg/week. 12 patients (31.6%) stopped treatment; in 8 cases this was due to toxicity, in 2 cases to lack to efficacy and in 2 cases to toxicity and lack of efficacy. For 19 patients, P-IFN treatment elicited a clinical response, in terms of relief from constitutional symptoms and reduction of phlebotomy frequency, or a laboratory response, in terms of reduction of allelic load for the JAK2 mutation. 3 patients did not experience a response to treatment and for the other patient this evaluation is currently premature.

Conclusion Our data confirmed the efficacy and tolerability of P-IFN. Our study has some limits, due to the small number of patients and to their heterogeneity. Further data collection is needed to confirm these preliminary data, together with a cost-efficacy evaluation.

References and/or acknowledgements Pai SG, Kaplan JB, Giles FJ. Long-acting interferon for myeloproliferative neoplasms—an update. Expert Rev Hematol2016;9:915–7. doi:10.1080/17474086.2016.1231571. Epub 2016 Sep 13.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.